Search research articles
Contact Us
Filters
Showing results (141-150 of 170) with videos related to
Page
of 17
Sort By:
American Journal of Respiratory and Critical Care Medicine
|
July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
Payam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Emerging Infectious Diseases
|
March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Ekaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial
Ava Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
The Journal of Infectious Diseases
|
April 6, 2012
Clinical research and development of tuberculosis diagnostics: moving from silos to synergy
Payam Nahid, Peter S Kim, Carlton A Evans, et al.
Emerging Infectious Diseases
|
January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020
Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The New England Journal of Medicine
|
March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Susan Swindells, Ritesh Ramchandani, Amita Gupta, et al.
Plos One
|
March 17, 2023
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household
Soyeon Kim, Anneke C Hesseling, Xingye Wu, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 170) with videos related to
Sort By:
Page
of 17
American Journal of Respiratory and Critical Care Medicine
|
July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap
Payam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Emerging Infectious Diseases
|
March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Ekaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial
Ava Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
The Journal of Infectious Diseases
|
April 6, 2012
Clinical research and development of tuberculosis diagnostics: moving from silos to synergy
Payam Nahid, Peter S Kim, Carlton A Evans, et al.
Emerging Infectious Diseases
|
January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020
Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 20, 2023
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
The New England Journal of Medicine
|
March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
Susan Swindells, Ritesh Ramchandani, Amita Gupta, et al.
Plos One
|
March 17, 2023
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household
Soyeon Kim, Anneke C Hesseling, Xingye Wu, et al.
Page
of 17